{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 73,
  "pageCount": 366,
  "prevPage": 72,
  "nextPage": 74,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a 'preempt_rebuttal' strategy by highlighting that even industry giants failed where the current subject company is operating.",
  "elementsJson": [
    "paragraph",
    "other"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/73",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-73",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Most pharma companies with an H3 receptor program documented their struggles and failures in published papers, and others announced trials and then went radio silent – an indicator of failure.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cce-94bd522699e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.58
      },
      "kind": "list",
      "text": "J&J failed phase 2 trial for narcolepsy\nA Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "305fb3f9-9584-402f-a182-f3ece372ac17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.84
      },
      "kind": "list",
      "text": "Pfizer failed phase 2 trial for narcolepsy with EDS\nA Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a377fe1-c057-4a64-9dcc-47f42a9fbb68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.07,
        "y": 0.71
      },
      "kind": "list",
      "text": "GlaxoSmithKline failed phase 2 trial for narcolepsy\nEffectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c4bdffa-53b2-4e1c-8a82-6bcc65ca59da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.55,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "list",
      "text": "J&J paper in 2007 documented efforts since 1990’s\nHistamine H3 receptor antagonists: From target identification to drug leads",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb06aad9-8aab-4f80-8b26-f5877159da2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Most pharma companies with an H3 receptor program documented their struggles and failures in published papers, and others announced trials and then went radio silent – an indicator of failure. For example, J&J published a paper in 2007 listing various compounds they tried since the 1990’s. They also initiated a phase 2 narcolepsy trial in 2007 which failed. Every other large pharma company’s narcolepsy trials or development programs were a bust as well. Glaxo had its own phase 2 narcolepsy study from 2006 to 2008, which was terminated. Pfizer’s compound failed a phase 2 for the same indication as pitolisant – EDS with narcolepsy.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01bacc3b-ed27-458b-9c4d-93750932366e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "preempt_rebuttal",
      "slug": null,
      "matchId": "90c23b7f-079b-4a34-a436-2cc7ad366cd8",
      "evidence": "The slide lists historical failures of competitors to frame the difficulty of the market and preemptively address skepticism about the company's success.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}